CO5650230A2 - Composiciones estables de atorvastatina preparadas con granulacion en humedo - Google Patents

Composiciones estables de atorvastatina preparadas con granulacion en humedo

Info

Publication number
CO5650230A2
CO5650230A2 CO05124741A CO05124741A CO5650230A2 CO 5650230 A2 CO5650230 A2 CO 5650230A2 CO 05124741 A CO05124741 A CO 05124741A CO 05124741 A CO05124741 A CO 05124741A CO 5650230 A2 CO5650230 A2 CO 5650230A2
Authority
CO
Colombia
Prior art keywords
atorvastatin
dosage form
unit dosage
weight
pharmaceutical composition
Prior art date
Application number
CO05124741A
Other languages
English (en)
Spanish (es)
Inventor
Kenneth Craig Waterman
Michael Bruce Fergione
Barbara Alice Johnson
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of CO5650230A2 publication Critical patent/CO5650230A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
CO05124741A 2003-06-12 2005-12-09 Composiciones estables de atorvastatina preparadas con granulacion en humedo CO5650230A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47811903P 2003-06-12 2003-06-12

Publications (1)

Publication Number Publication Date
CO5650230A2 true CO5650230A2 (es) 2006-06-30

Family

ID=33551806

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05124741A CO5650230A2 (es) 2003-06-12 2005-12-09 Composiciones estables de atorvastatina preparadas con granulacion en humedo

Country Status (15)

Country Link
EP (1) EP1635814A1 (no)
JP (1) JP2006527260A (no)
KR (1) KR100814218B1 (no)
CN (1) CN100434069C (no)
AR (1) AR044774A1 (no)
AU (1) AU2004246868B2 (no)
BR (1) BRPI0411344A (no)
CA (1) CA2465565A1 (no)
CO (1) CO5650230A2 (no)
MX (1) MXPA05013281A (no)
NO (1) NO20060022L (no)
NZ (1) NZ543337A (no)
RU (1) RU2332211C2 (no)
TW (1) TW200503690A (no)
WO (1) WO2004110431A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
EP2170294A1 (en) * 2007-06-25 2010-04-07 Pharmathen S.A. Improved pharmaceutical formulation containing an hmg-coa reductase inhibitor and method for the preparation thereof
CN102089016A (zh) * 2008-02-27 2011-06-08 托门医学股份公司 植入物及其制备方法
AU2009292615B2 (en) * 2008-09-17 2015-12-03 Mylan Inc. Granulates, process for preparing them and pharmaceutical products containing them
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
WO2013072770A2 (en) 2011-11-15 2013-05-23 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising atorvastatin and glimepiride
CN104069078B (zh) * 2014-05-22 2019-06-11 西藏九瑞健康股份有限公司 阿托伐他汀钙药物组合物及其制备方法
SG10201900648SA (en) * 2014-07-25 2019-02-27 Novartis Ag Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
KR101658350B1 (ko) * 2015-02-06 2016-09-30 경성대학교 산학협력단 고지혈증 치료에 유용한 약학 조성물
EP3267977B1 (en) * 2015-03-12 2021-08-11 DuPont Nutrition USA, Inc. Solid dispersions
JPWO2017170858A1 (ja) 2016-03-31 2019-02-14 インターセプト ファーマシューティカルズ， インコーポレイテッド 溶出性に優れた経口製剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016693A1 (en) * 1993-01-19 1994-08-04 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
JPH06242003A (ja) * 1993-02-12 1994-09-02 Nkk Corp 鉄鋼中のアルミナの粒度測定方法
JP3014040B2 (ja) * 1996-10-30 2000-02-28 信久 川野 食物繊維パン及びその製造法
EP2382970B1 (en) * 2000-04-10 2013-01-09 Teva Pharmaceutical Industries, Ltd. Stable Pharmaceutical Compositions Containing 7-Substituted-3,5-Dihydroxyheptanoic Acids or 7-Substituted-3,5-Dihydroxyheptenoic Acids
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
EP1226818A1 (en) * 2001-01-26 2002-07-31 Pfizer Products Inc. Pharmaceutical dosage forms with enhanced cohesive and compressibility properties
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij

Also Published As

Publication number Publication date
CN1805741A (zh) 2006-07-19
NO20060022L (no) 2006-01-03
CN100434069C (zh) 2008-11-19
NZ543337A (en) 2008-03-28
AR044774A1 (es) 2005-10-05
RU2005136745A (ru) 2006-07-27
AU2004246868B2 (en) 2008-01-17
RU2332211C2 (ru) 2008-08-27
TW200503690A (en) 2005-02-01
EP1635814A1 (en) 2006-03-22
BRPI0411344A (pt) 2006-07-11
AU2004246868A1 (en) 2004-12-23
KR100814218B1 (ko) 2008-03-17
MXPA05013281A (es) 2006-03-09
CA2465565A1 (en) 2004-12-12
WO2004110431A1 (en) 2004-12-23
KR20060020666A (ko) 2006-03-06
JP2006527260A (ja) 2006-11-30

Similar Documents

Publication Publication Date Title
CO5650230A2 (es) Composiciones estables de atorvastatina preparadas con granulacion en humedo
AR038527A1 (es) Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo
CO5640071A2 (es) Composiciones farmaceuticas de atorvastatina
EA200801926A1 (ru) Таблетки парацетамола с быстрым высвобождением
CO5390076A1 (es) Composiciones farmaceuticas
CO5640087A2 (es) Composiciones de farmacos anti-inflamatorios no esteroideos descongestionantes y anti-histaminicos
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
ES2181417T3 (es) Formulacion de capsulas o tabletas de efavirenz de disolucion rapida usando super-desintegrantes.
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
CO5640072A2 (es) Composiciones farmaceuticas que comprenden atorvastatina fabricada sin granulacion
BRPI0515345A (pt) comprimidos de liberação gastrointestinal com local e hora controlados de ingrediente ativo
ATE386508T1 (de) Feste orale dosierungsform enthaltend einen resorptionsverstärker
UY24613A1 (es) Formula de liberacion controlada que comprende venlafaxina
AR050615A1 (es) Composiciones farmaceuticas para la administracion oral
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
CO5280073A1 (es) Composiciones
AR037930A1 (es) Formulaciones de acitromicina directamente compresibles
UA116334C2 (uk) Тверді форми дозування бендамустину
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
RS53087B (en) SOLID PHARMACEUTICAL COMPOSITIONS OF PERMANENT COMPOSITION CONTAINING IRBESARTAN AND AMLODIPINE, THEIR PREPARATION AND THERAPY USE
HUP0301390A2 (hu) Valzartánt tartalmazó orális gyógyászati készítmény
MXPA03011317A (es) Comprimido masticable que comprende paracetamol.
RU2006115784A (ru) Применение l-бутилфталида для изготовления лекарственного средства для профилактики и лечения церебрального инфаркта
ZA200506992B (en) Fibrate tablet and method for the production thereof
ATE410152T1 (de) Therapeutisches system mit amoxicillin und clavulansäure

Legal Events

Date Code Title Description
FC Application refused